Reviews Alora


No reviews yet.

Alora Drug Description
Alora®
(estradiol) Transdermal System
Continuous Delivery for Twice Weekly Dosing

ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER.
Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures, including endometrial sampling when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is currently no evidence that
the use of "natural" estrogens results in a different endometrial
risk profile than synthetic estrogens of equivalent estrogen dose. (See WARNINGS,
Malignant neoplasms, Endrometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with and without progestins should not be used for the prevention
of cardiovascular disease or dementia. (See WARNINGS,
Cardiovascular disorders and Dementia.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical
Studies and WARNINGS, Cardiovascular disorders and Malignant neoplasms,
Breast cancer.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women. (See CLINICAL PHARMACOLOGY,
Clinical Studies and WARNINGS, Dementia and PRECAUTIONS,
Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials and, in the absence of comparable data, these
risks should be assumed to be similar. Because of these risks, estrogens with
or without progestins should be prescribed at the lowest effective doses and
for the shortest duration consistent with treatment goals and risks for the
individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol transdermal?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden headache, confusion, problems with vision, speech, or...
Read All Potential Side Effects for Alora »




Alora (estradiol transdermal system) is designed to deliver estradiol continuously
and consistently over a 3 or 4-day interval upon application to intact skin.
Four strengths of Alora are available, having nominal in vivo delivery
rates of 0.025, 0.05, 0.075, and 0.1 mg estradiol per day through skin of average
permeability (inter-individual variation in skin permeability is approximately
20%). Alora has contact surface areas of 9, 18, 27, and 36 cm2 and
contains 0.77, 1.5, 2.3, and 3.1 mg of estradiol, USP, respectively. The composition
of the estradiol transdermal systems per unit area is identical. Estradiol,
USP is a white, crystalline powder that is chemically described as estra-1,3,5(10)-triene-3,
17β-diol, has an empirical formula of C18H24O2
and has molecular weight of 272.39. The structural formula is:








Alora consists of three layers. Proceeding from the polyethylene backing film
as shown in the cross-sectional view below, the adhesive matrix drug reservoir
that is in contact with the skin consists of estradiol, USP and sorbitan monooleate
dissolved in an acrylic adhesive matrix. The polyester overlapped release liner
protects the adhesive matrix during storage and is removed prior to application
of the system to the skin.







Last reviewed on RxList: 10/23/2008




Alora Drug Description
Alora®
(estradiol) Transdermal System
Continuous Delivery for Twice Weekly Dosing

ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER.
Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures, including endometrial sampling when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is currently no evidence that
the use of "natural" estrogens results in a different endometrial
risk profile than synthetic estrogens of equivalent estrogen dose. (See WARNINGS,
Malignant neoplasms, Endrometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with and without progestins should not be used for the prevention
of cardiovascular disease or dementia. (See WARNINGS,
Cardiovascular disorders and Dementia.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical
Studies and WARNINGS, Cardiovascular disorders and Malignant neoplasms,
Breast cancer.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women. (See CLINICAL PHARMACOLOGY,
Clinical Studies and WARNINGS, Dementia and PRECAUTIONS,
Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials and, in the absence of comparable data, these
risks should be assumed to be similar. Because of these risks, estrogens with
or without progestins should be prescribed at the lowest effective doses and
for the shortest duration consistent with treatment goals and risks for the
individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol transdermal?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden headache, confusion, problems with vision, speech, or...
Read All Potential Side Effects for Alora »




Alora (estradiol transdermal system) is designed to deliver estradiol continuously
and consistently over a 3 or 4-day interval upon application to intact skin.
Four strengths of Alora are available, having nominal in vivo delivery
rates of 0.025, 0.05, 0.075, and 0.1 mg estradiol per day through skin of average
permeability (inter-individual variation in skin permeability is approximately
20%). Alora has contact surface areas of 9, 18, 27, and 36 cm2 and
contains 0.77, 1.5, 2.3, and 3.1 mg of estradiol, USP, respectively. The composition
of the estradiol transdermal systems per unit area is identical. Estradiol,
USP is a white, crystalline powder that is chemically described as estra-1,3,5(10)-triene-3,
17β-diol, has an empirical formula of C18H24O2
and has molecular weight of 272.39. The structural formula is:








Alora consists of three layers. Proceeding from the polyethylene backing film
as shown in the cross-sectional view below, the adhesive matrix drug reservoir
that is in contact with the skin consists of estradiol, USP and sorbitan monooleate
dissolved in an acrylic adhesive matrix. The polyester overlapped release liner
protects the adhesive matrix during storage and is removed prior to application
of the system to the skin.







Last reviewed on RxList: 10/23/2008




Alora Drug Description
Alora®
(estradiol) Transdermal System
Continuous Delivery for Twice Weekly Dosing

ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER.
Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures, including endometrial sampling when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is currently no evidence that
the use of "natural" estrogens results in a different endometrial
risk profile than synthetic estrogens of equivalent estrogen dose. (See WARNINGS,
Malignant neoplasms, Endrometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with and without progestins should not be used for the prevention
of cardiovascular disease or dementia. (See WARNINGS,
Cardiovascular disorders and Dementia.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical
Studies and WARNINGS, Cardiovascular disorders and Malignant neoplasms,
Breast cancer.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women. (See CLINICAL PHARMACOLOGY,
Clinical Studies and WARNINGS, Dementia and PRECAUTIONS,
Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials and, in the absence of comparable data, these
risks should be assumed to be similar. Because of these risks, estrogens with
or without progestins should be prescribed at the lowest effective doses and
for the shortest duration consistent with treatment goals and risks for the
individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol transdermal?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden headache, confusion, problems with vision, speech, or...
Read All Potential Side Effects for Alora »




Alora (estradiol transdermal system) is designed to deliver estradiol continuously
and consistently over a 3 or 4-day interval upon application to intact skin.
Four strengths of Alora are available, having nominal in vivo delivery
rates of 0.025, 0.05, 0.075, and 0.1 mg estradiol per day through skin of average
permeability (inter-individual variation in skin permeability is approximately
20%). Alora has contact surface areas of 9, 18, 27, and 36 cm2 and
contains 0.77, 1.5, 2.3, and 3.1 mg of estradiol, USP, respectively. The composition
of the estradiol transdermal systems per unit area is identical. Estradiol,
USP is a white, crystalline powder that is chemically described as estra-1,3,5(10)-triene-3,
17β-diol, has an empirical formula of C18H24O2
and has molecular weight of 272.39. The structural formula is:








Alora consists of three layers. Proceeding from the polyethylene backing film
as shown in the cross-sectional view below, the adhesive matrix drug reservoir
that is in contact with the skin consists of estradiol, USP and sorbitan monooleate
dissolved in an acrylic adhesive matrix. The polyester overlapped release liner
protects the adhesive matrix during storage and is removed prior to application
of the system to the skin.







Last reviewed on RxList: 10/23/2008




Alora Drug Description
Alora®
(estradiol) Transdermal System
Continuous Delivery for Twice Weekly Dosing

ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER.
Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures, including endometrial sampling when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is currently no evidence that
the use of "natural" estrogens results in a different endometrial
risk profile than synthetic estrogens of equivalent estrogen dose. (See WARNINGS,
Malignant neoplasms, Endrometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with and without progestins should not be used for the prevention
of cardiovascular disease or dementia. (See WARNINGS,
Cardiovascular disorders and Dementia.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical
Studies and WARNINGS, Cardiovascular disorders and Malignant neoplasms,
Breast cancer.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women. (See CLINICAL PHARMACOLOGY,
Clinical Studies and WARNINGS, Dementia and PRECAUTIONS,
Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials and, in the absence of comparable data, these
risks should be assumed to be similar. Because of these risks, estrogens with
or without progestins should be prescribed at the lowest effective doses and
for the shortest duration consistent with treatment goals and risks for the
individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol transdermal?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden headache, confusion, problems with vision, speech, or...
Read All Potential Side Effects for Alora »




Alora (estradiol transdermal system) is designed to deliver estradiol continuously
and consistently over a 3 or 4-day interval upon application to intact skin.
Four strengths of Alora are available, having nominal in vivo delivery
rates of 0.025, 0.05, 0.075, and 0.1 mg estradiol per day through skin of average
permeability (inter-individual variation in skin permeability is approximately
20%). Alora has contact surface areas of 9, 18, 27, and 36 cm2 and
contains 0.77, 1.5, 2.3, and 3.1 mg of estradiol, USP, respectively. The composition
of the estradiol transdermal systems per unit area is identical. Estradiol,
USP is a white, crystalline powder that is chemically described as estra-1,3,5(10)-triene-3,
17β-diol, has an empirical formula of C18H24O2
and has molecular weight of 272.39. The structural formula is:








Alora consists of three layers. Proceeding from the polyethylene backing film
as shown in the cross-sectional view below, the adhesive matrix drug reservoir
that is in contact with the skin consists of estradiol, USP and sorbitan monooleate
dissolved in an acrylic adhesive matrix. The polyester overlapped release liner
protects the adhesive matrix during storage and is removed prior to application
of the system to the skin.







Last reviewed on RxList: 10/23/2008




Alora Drug Description
Alora®
(estradiol) Transdermal System
Continuous Delivery for Twice Weekly Dosing

ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER.
Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures, including endometrial sampling when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is currently no evidence that
the use of "natural" estrogens results in a different endometrial
risk profile than synthetic estrogens of equivalent estrogen dose. (See WARNINGS,
Malignant neoplasms, Endrometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with and without progestins should not be used for the prevention
of cardiovascular disease or dementia. (See WARNINGS,
Cardiovascular disorders and Dementia.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical
Studies and WARNINGS, Cardiovascular disorders and Malignant neoplasms,
Breast cancer.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women. (See CLINICAL PHARMACOLOGY,
Clinical Studies and WARNINGS, Dementia and PRECAUTIONS,
Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials and, in the absence of comparable data, these
risks should be assumed to be similar. Because of these risks, estrogens with
or without progestins should be prescribed at the lowest effective doses and
for the shortest duration consistent with treatment goals and risks for the
individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol transdermal?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden headache, confusion, problems with vision, speech, or...
Read All Potential Side Effects for Alora »




Alora (estradiol transdermal system) is designed to deliver estradiol continuously
and consistently over a 3 or 4-day interval upon application to intact skin.
Four strengths of Alora are available, having nominal in vivo delivery
rates of 0.025, 0.05, 0.075, and 0.1 mg estradiol per day through skin of average
permeability (inter-individual variation in skin permeability is approximately
20%). Alora has contact surface areas of 9, 18, 27, and 36 cm2 and
contains 0.77, 1.5, 2.3, and 3.1 mg of estradiol, USP, respectively. The composition
of the estradiol transdermal systems per unit area is identical. Estradiol,
USP is a white, crystalline powder that is chemically described as estra-1,3,5(10)-triene-3,
17β-diol, has an empirical formula of C18H24O2
and has molecular weight of 272.39. The structural formula is:








Alora consists of three layers. Proceeding from the polyethylene backing film
as shown in the cross-sectional view below, the adhesive matrix drug reservoir
that is in contact with the skin consists of estradiol, USP and sorbitan monooleate
dissolved in an acrylic adhesive matrix. The polyester overlapped release liner
protects the adhesive matrix during storage and is removed prior to application
of the system to the skin.







Last reviewed on RxList: 10/23/2008





Other reviews about Alora on wordpress

ALORA¬īS HEALTH CENTRE TO OPEN SOON
  by towncriernewspaper
Alora Mayor Jos√© S√°nchez Moreno said last week that he expects the town's new health centre to open by the end of the year. Representatives of the Town […]


Alora, Spain
  by His
Each¬†morning at 9:15 a.m.¬†the MMC family¬†begins the day with¬†prayer. On Friday the emphasis is on the Spanish ministry. Today Jeber (pronounced Abear), short-term from Brazil, spoke to the […]


Alora's First Christmas
  by barhamfamily
Alora slept through a lot of her first Christmas, but everyone had so much fun holding her...and buying her presents. She got toys and music from Grammi Lori, […]


ALORA BUCKS CONSTRUCTIONS TRENDS
  by towncriernewspaper
While construction has fallen in the rest of Malaga province, it rose by over 30% in Alora last year. The town's Businessmen's Association reported that licences for more […]


Alora's First Easter & Kel's 25th
  by barhamfamily
Alora's first Easter was celebrated right along with my 25th birthday. We had my family and Nate's family over to Mom & Larry's for Easter dinner. We […]


Alora's Soccer
  by sixdurans
So the only time I actually remembered to bring the camera to Alora's games was the final game. Well it was pouring rain, windy, and I had 4 […]


Disneyland Day Two
  by sixdurans
Day two at Disneyland brought the rain - lots and lots of rain. It was pouring, windy, and extremely cold for Southern California. So I stayed back in […]


7th Perota Soup Day in √Ālora announced
  by costadelsoltouristboard
09/30/2009 http://professionals.visitcostadelsol.com/bd/mostrar_noticia.php?ident=827&tipo=eventos ‚Äú√Ālora makes the soup, you bring your spoon.‚ÄĚ This is the motto of what has become one of the most popular events in M√°laga Province: Perota Soup […]


Places of interest in Spain ‚Äď Alora
  by denywillson
Be sure, you will certainly enjoy your stay in Spain. It has all that you require as a tourist; a quiet and entertaining place to stay and relax, […]


alora
  by deviabraham
Alora is a filler word in Italian. Our waitresses came to the table, and usually the first word out of their mouth was, "Alora..." It sounds like a […]



Other reviews about Alora on web:

Alora Ambiance Home Fragrances √ʬĬď Diffusers and Candles. ... Free shipping on orders of $100 or more and free vial kit with orders of $150 or more. Alora Ambiance Home Fragrances


Search the Watson Pharmaceuticals Database for a broad array of brand and generic pharmaceutical products. Alora


Learn about the prescription medication Alora (Estradiol Transdermal System), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Alora (Estradiol Transdermal System) Drug Information: Uses, Side ...


√ɬĀlora is a town of southern Spain, part of the M√ɬ°laga, c. 40 km from M√ɬ°laga, on the right bank of the river Guadalhorce, and on the C√ɬ≥rdoba-M√ɬ°laga high-speed rail line. √ɬĀlora - Wikipedia, the free encyclopedia


Alora: Alora (drug), a brand name for transdermal Estradiol; √ɬĀlora, a town in southern Spain Alora - Wikipedia, the free encyclopedia


Accurate, FDA approved Alora information for healthcare professionals and patients - brought to you by Drugs.com. Alora Official FDA information, side effects and uses.


Alora Home Health Software integrates 485, Scheduling, Billing, OASIS, Point of Care, A/R and much more in one easy-to-use home health software application. Alora Home Care ... Home Health Software - Alora Home Care Software


Comprehensive and trusted information about Alora - plus advice on 24,000 other FDA approved drugs and medications from Drugs.com. Alora patient advice including side effects


Information about the village of Alora in the Province of Malaga, Andalucía, Southern Spain. The village of Alora in the Malaga province, Andalucía, Southern ...


Alora is a skin patch containing estrogen that is used for treating menopause symptoms. This page from the eMedTV archives further explains what Alora is used for, offers tips on ... Alora





Featured Reviews

Reviews Methylergonovine Maleate

Methergine Drug Description Methergine® (methylergonovine maleate) Tablets, USP (methylergonovine maleate) Injection, USP DRUG DESCRIPTION What are the possible side effects of methylergonovine (Methergine)? Get emergency...
Read More  |  Review This
Reviews Cytoxan

Cytoxan Drug Description CYTOXAN® (cyclophosphamide) for Injection, USP CYTOXAN® Tablets (cyclophosphamide) Tablets, USP DRUG DESCRIPTION What are the possible side effects of cyclophosphamide (Cytoxan, Cytoxan Lyophilized,...
Read More  |  Review This
Reviews Nembutal

Nembutal Drug Description NEMBUTAL® Sodium Solution (pentobarbital sodium) Injection, USP DO NOT USE IF MATERIAL HAS PRECIPITATED DRUG DESCRIPTION What are the possible side effects of pentobarbital (Nembutal Sodium)? Get emergency...
Read More  |  Review This
Reviews Desogen

Desogen Drug Description Desogen® (desogestrel and ethinyl estradiol tablets) Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually trans-mitted diseases. DRUG DESCRIPTION Wha...
Read More  |  Review This
Reviews Ondansetron Hydrochloride Injection

Zofran Injection Drug Description ZOFRAN® (ondansetron hydrochloride) Injection ZOFRAN® (ondansetron hydrochloride) Injection Premixed DRUG DESCRIPTION What are the possible side effects of ondansetron injection (Zofran)? Get...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....